Condition
Protein-Losing Enteropathies
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Completed2
Unknown1
Enrolling By Invitation1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02315898Phase 2Completed
Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis
NCT03322345Enrolling By Invitation
Characterizing the Effect of Dopamine on Markers of Lymph Re-circulation in Fontan-associated Protein-losing Enteropathy
NCT04163653Completed
Lymphatic Morphology of Fontan Patients
NCT03950804Unknown
Transcriptome and Metabolic Analyses of CHAPLE Disease
Showing all 4 trials